Current Infectious Disease Reports

, Volume 9, Issue 2, pp 151–158

Human papillomavirus vaccine update


DOI: 10.1007/s11908-007-0011-6

Cite this article as:
Ames, A. & Gravitt, P. Curr Infect Dis Rep (2007) 9: 151. doi:10.1007/s11908-007-0011-6


With the approval of Gardasil® (Merck and Co., Inc., Whitehouse Station, NJ) in June of 2006 and the pending approval of Cervarix® (GlaxoSmithKline, London, UK), two prophylactic human papillomavirus (HPV) vaccines will be available for clinical use. Randomized controlled trials have shown that both vaccines are safe and highly effective in preventing persistent infection and lesions caused by HPV 16 and 18—the types responsible for 70% of cervical cancers worldwide. Determining an effective vaccination strategy is now the most pressing issue facing clinicians, parents, public health officials, and policy makers. We discuss the appropriate age of vaccination, vaccine acceptance, implementation strategies in low resource settings, and the future of screening.

Copyright information

© Current Medicine Group, LLC 2007

Authors and Affiliations

  1. 1.Department of Epidemiology and Molecular Microbiology and ImmunologyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA

Personalised recommendations